Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India
Brolucizumab 6 mg IVI, given as per the prescribing information, demonstrated a positive benefit/risk profile in Indian patients with nAMD, with no new safety signals.
Authors
- Simar Rajan Singh (ORCID: https://orcid.org/0000-0003-0207-1913)
- Maulik Bhavsar (ORCID: https://orcid.org/0000-0001-9633-2146)
- Aditya Sudhalkar (ORCID: https://orcid.org/0000-0001-8426-2611)
- Rohan Chawla (ORCID: https://orcid.org/0000-0002-6791-4435)
- Ramesh Venkatesh (ORCID: https://orcid.org/0000-0002-4479-9390)
- Anup Thorat
- Vishal Raval (ORCID: https://orcid.org/0000-0002-8446-2696)
- Sonali Shah
- Debdulal Chakraborty (ORCID: https://orcid.org/0000-0001-9693-7882)
- S. D. Patil (ORCID: https://orcid.org/0000-0002-4166-2604)
- Amiya R. Sahu
- Asim K. Ghosh (ORCID: https://orcid.org/0000-0003-4528-8602)
- Padma Preetha
- Isha Khadke
Institutions
- L V Prasad Eye Institute (IN)
- Ahmedabad Civil Hospital (IN)
- Novartis (India) (IN)
- Raghudeep Eye Hospital (IN)
- Institute of Neurosciences Kolkata (IN)
- Narayana Nethralaya (IN)
- Dr. Agarwal's Eye Hospital (IN)
- Post Graduate Institute of Medical Education and Research (IN)
- All India Institute of Medical Sciences (IN)
Publication Details
- Journal
- Indian Journal of Ophthalmology
- Published
- 2025-04-17
- DOI
- https://doi.org/10.4103/ijo.ijo_1914_24
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00